Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications

The coronavirus disease 2019 (COVID‐19) antiviral nirmatrelvir/ritonavir (Paxlovid) has been granted authorization or approval in several countries for the treatment of patients with mild to moderate COVID‐19 at high risk of progression to severe disease and with no requirement for supplemental oxyg...

Descripción completa

Detalles Bibliográficos
Autores principales: Marzolini, Catia, Kuritzkes, Daniel R., Marra, Fiona, Boyle, Alison, Gibbons, Sara, Flexner, Charles, Pozniak, Anton, Boffito, Marta, Waters, Laura, Burger, David, Back, David J., Khoo, Saye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348462/
https://www.ncbi.nlm.nih.gov/pubmed/35567754
http://dx.doi.org/10.1002/cpt.2646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348462/
https://www.ncbi.nlm.nih.gov/pubmed/35567754
http://dx.doi.org/10.1002/cpt.2646

Ejemplares similares